<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">INSULIN GLULISINE</span><br/>(in'su-lin glu-li'seen)<br/><span class="topboxtradename">Apidra<br/></span><b>Classifications:</b> <span class="classification">hormones &amp; synthetic substitutes</span>; <span class="classification">antidiabetic agent; insulin</span><br/><b>Prototype: </b>Insulin Injection (Regular)<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 units/mL multidose (10 mL) vials</p>
<h1><a name="action">Actions</a></h1>
<p>Insulin glulisine, formed by recombinant DNA, is a rapid-acting insulin. Insulin lowers blood glucose by stimulating peripheral
         glucose uptake by skeletal muscle and fat and by inhibiting hepatic glucose production. Insulin causes lipolysis in the adipocyte,
         inhibits proteolysis, and enhances protein synthesis.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Insulin glulisine has a more rapid onset of action and a shorter duration of action than regular human insulin; thus, it provides
         good postprandial blood glucose control.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of diabetes mellitus.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypoglycemia; systemic allergy to insulin; pregnancy (category C). Safety and effectiveness in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Renal impairment, hepatic dysfunction; lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Diabetes<b></b>
</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC</span> 510 units within 15 min before starting a meal or within 20 min after starting a meal. Dose should be individualized.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Subcutaneous</span><br/><ul>
<li>Give within 15 min before or up to 20 min after a meal.</li>
<li>Store refrigerated at 36° F to 46° F (2° C to 8° C). Discard vial if frozen. Protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">[see <small>INSULIN (REGULAR)</small>] Body as a Whole:</span> Allergic reactions. <span class="typehead">Metabolic:</span> Hypoglycemia. <span class="typehead">Skin:</span> Injection site reactions, lipodystrophy, pruritus, rash. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>See Insulin Injection (Regular)</p>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 70% bioavailable from injection sites. <span class="typehead">Peak:</span> 55 min. <span class="typehead">Duration:</span> 140150 min. <span class="typehead">Metabolism:</span> Metabolized primarily in liver with some metabolism in the kidney. <span class="typehead">Half-Life:</span> 42 min SC. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of hypoglycemia (see Appendix F). Initial hypoglycemic response begins within 15 min and peaks, on average,
            4060 min after injection.
         </li>
<li>Lab tests: Periodically monitor fasting and postprandial blood glucose and HbA<sub>1C</sub>.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not inject into areas with redness, swelling, itching, or dimpling.</li>
<li>If mixing with NPH human insulin, draw up insulin glulisine first. Inject immediately after mixing.</li>
<li>Ingest some form of sugar (e.g., orange juice, dissolved table sugar, honey) if symptoms of hypoglycemia develop, and seek
            medical assistance.
         </li>
<li>Check blood sugar as prescribed, especially postprandial values; notify physician of fasting blood glucose 140 mg/dL.</li>
<li>Notify the physician of any of the following: fever, infection, trauma, diarrhea, nausea, or vomiting. Dosage adjustment may
            be needed.
         </li>
<li>Do not take any other medication unless approved by the physician.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>